Evidence map›Paper›PMID 34101010›Full record

Trial reportEuropean journal of pediatrics2021

Lactoferrin versus iron hydroxide polymaltose complex for the treatment of iron deficiency anemia in children with cerebral palsy: a randomized controlled trial.

Omneya M Omar, Hala Assem, Doaa Ahmed, Marwa S Abd Elmaksoud

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06232642 (The Effects of Lactoferrin and Iron-enriched Whey on Iron Status of Active Collegiate Females), which is not on this map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06232642 naunknown statusnot on this mapstarted 2024, after this paper: background citation

The Effects of Lactoferrin and Iron-enriched Whey on Iron Status of Active Collegiate Females

TypeinterventionalSponsorUtah State UniversityRan2024 to 2025Enrolled82ConditionsSerum FerritinArmsLactoferrin, iron and B12 in Whey Protein, Lactoferrin, Iron and B12 in Rice Protein, Lactoferrin, Iron and B12 in Maltrodextrin
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Clinical research review: usefulness of bovine lactoferrin in child health.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Omneya M OmarDepartment of Pediatrics, Metabolism and Nutrition Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt. o_magdy09@alexmed.edu.eg.ORCID http://orcid.org/0000-0003-1967-8893
Hala AssemDepartment of Pediatrics, Hematology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt.ORCID https://orcid.org/0000-0002-1149-4662
Doaa AhmedDepartment of Pediatrics, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Marwa S Abd ElmaksoudDepartment of Pediatrics, Neurology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt.ORCID https://orcid.org/0000-0001-5827-4459
Alexandria University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron deficiency anemia (IDA) is common among children with cerebral palsy (CP), and studies on the efficacy of lactoferrin (Lf) in the treatment of IDA are limited. This study aimed to compare the efficacy of Lf with that of iron hydroxide polymaltose complex (IPC) in the treatment of IDA in children with CP. This randomized controlled study, conducted at Alexandria University Children's Hospital, enrolled 70 children aged 1-10 years with CP and IDA; 35 children randomly received IPC, whereas the other 35 received Lf. Four children withdrew from the study; thus, only 66 children were analyzed (32 in the IPC group and 34 in the Lf group). At baseline, the hemoglobin level and other blood parameters were similar between the two intervention groups. After four weeks of treatment, both the IPC and Lf groups showed significant improvements in hemoglobin (Hb), serum ferritin (SF), serum iron, total iron-binding capacity, mean corpuscular volume, and mean corpuscular hemoglobin from baseline. Upon comparing the two treatment groups, adjusted mean Hb and SF changes in the Lf group were significantly higher than that of the IPC group (p =0.001and p= 0.033, respectively), and constipation was less likely to occur in the Lf group than the IPC group (p = 0.049 ).Conclusion: Lactoferrin is effective and superior to IPC as an oral iron replacement therapy in children with CP and IDA, as it has fewer side effects. What is Known: • Lactoferrin (LF) is a natural glycoprotein capable of treating iron deficiency anemia (IDA). • Studies on the efficacy of Lf in the treatment of IDA in children with cerebral palsy (CP) are limited. What is New? • This trial compared the efficacy of Lf and iron hydroxide polymaltose complex (IPC) as treatments of IDA in children with CP. • Lf is effective and even better than IPC as a treatment of IDA in children with CP, as it has fewer side effects.

Indexed as

Anemia, Iron-DeficiencyCerebral PalsyChildFerric CompoundsHemoglobinsHumansLactoferrinFerric CompoundsHemoglobinsLactoferrinteferrolCerebral palsyIron deficiency anemiaIron hydroxide polymaltose complexLactoferrin

Identifiers

PMID34101010
OpenAlexW3168176191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.